[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.194.190. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Invited Commentary
June 2017

Comparing Anti–Vascular Endothelial Growth Factor Therapies for Central Retinal Vein Occlusion

Author Affiliations
  • 1Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts
  • 2Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts
  • 3CME Editor, JAMA Ophthalmology
JAMA Ophthalmol. 2017;135(6):649-650. doi:10.1001/jamaophthalmol.2017.1142

Central retinal vein occlusion (CRVO) is a common problem encountered in general ophthalmology and retina clinics worldwide. Macular edema can result from abnormal vascular permeability due to CRVO and lead to substantial vision loss in some patients if left untreated. Over the last decade, multiple clinical trials have established the efficacy of intravitreous anti–vascular endothelial growth factor (VEGF) therapy for improving visual acuity with CRVO. However, it has been largely unclear which, if any, of the available anti-VEGF agents provides the best functional or anatomic outcomes. Given substantial differences in cost and availability between anti-VEGF drugs, a rigorous comparison of efficacy and safety among the most widely used agents has major implications for both individual patient treatment decisions and public health policy.

×